FRI0619 INPATIENT BURDEN AND COMORBIDITIES OF SARCOIDOSIS: NATIONWIDE INPATIENT SAMPLE 2013–2014
Authors: Patompong Ungprasert, Karn Wijarnpreecha, Wisit Cheungpasitporn, Charat Thongprayoon, Paul Kroner
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Little is known about the inpatient burden and healthcare utilization among patients with sarcoidosis. Previous studies have focused on trends of hospitalization rate of patients with sarcoidosis over time [1] but none has investigated their inpatient prevalence, mortality and expenditures. <h3>Objectives</h3> The current study was conducted with the aims to shed more light on those characteristics as well as to investigate the comorbidities of sarcoidosis using the data from a large national database. <h3>Methods</h3> Patients with sarcoidosis were identified within the Nationwide Inpatient Sample (NIS) database of the years 2013 and 2014 using the ICD-9 diagnostic code. NIS is the largest publicly available inpatient database in the US. Data for more than seven million individual hospitalization across all-payers in the United States (US) is recorded annually in the NIS database. This is itself a 20% stratified sample of over 4,000 non-federal acute care hospitals from more than 40 states of the US and is representative of 95% of hospital discharges nationwide. Data on patient and hospital characteristics, comorbidities, total hospital costs and total hospitalization charges was collected. A propensity-matched cohort of patients without sarcoidosis from the same database was created and used as comparators for the analysis of comorbidities. Inpateint prevalence of sarcoidosis was calculated using all admissions in the NIS database as denominator. Odds ratios (OR) comapring the prevalence of comorbities between cases with sarcoidosis and propensity-matched controls without sarcoidosis were calculated. <h3>Results</h3> A cohort 78,055 patients with sarcoidosis was identified from the database, corresponding to an inpatient prevalence of 2.21 cases per 1,000 admissions. The most common reasons for admission among patients with sarcoidosis in this cohort were as follows; pneumonia (34.3%), respiratory failure (26.1%), cardiomyopathy (10.9%), coronary artery disease (9.2%), acute kidney injury (8.5%) and atrial fibrillation (5.5%). Analysis of comorbidities found that patients with sarcoidosis had significantly higher odds of atrial fibrillation, conduction abnormalities, aortic valvulopathy, congestive heart failure and cardiomyopathy compared to propensity-matched patients without sarcoidosis (table 1). After adjusting for confounders, patients with sarcoidosis displayed a mean additional $27,205 (p&lt;0.01) for total hospitalization charges (the amount of money that each hospital billed for providing its service on each case) when compared to hospitalization of patients without sarcoidosis. <h3>Conclusion</h3> The inpatient prevalence of sarcoidosis was relatively high compared to its overall incidence. Hospitalization of patients with sarcoidosis was associated with a significantly higher total hospitalization charges. Patients with sarcoidosis have higher risk of several cardiac comorbidities. <h3>References</h3> [1] Foreman MG, et al. (2006) Hospitalization for patients with sarcoidosis: 1979-2000. Sarcoidosis Vasc Diffuse Lung Dis23:124-129. <h3>Disclosure of Interests</h3> None declared